Isryl-M2 Tablet SR is a sustained-release oral antidiabetic medication combining Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in reduced blood glucose levels. The sustained-release formulation ensures a gradual release of active ingredients, promoting stable plasma concentrations, minimizing gastrointestinal side effects commonly associated with immediate-release metformin, and enhancing patient compliance through once-daily dosing. Isryl-M2 is particularly beneficial for patients inadequately controlled on monotherapy or lifestyle modifications alone. It should be administered with meals to reduce gastrointestinal discomfort. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis or hypoglycemia. Regular monitoring of blood glucose levels, renal function, and periodic assessment of hepatic parameters is recommended during therapy. Isryl-M2 Tablet SR should be used as part of a comprehensive diabetes management plan including diet, exercise, and weight control to achieve optimal glycemic control and reduce the risk of diabetes-related complications.